Invesco’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.35M Sell
132,103
-1,090,175
-89% -$19.5M ﹤0.01% 2511
2026
Q1
$21.9M Buy
1,222,278
+189,163
+18% +$4.13M ﹤0.01% 1408
2025
Q4
$27.9M Buy
1,033,115
+229,313
+29% +$6.46M ﹤0.01% 1298
2025
Q3
$24.3M Buy
803,802
+297,065
+59% +$9.47M ﹤0.01% 1371
2025
Q2
$13.5M Buy
+506,737
New +$13.7M ﹤0.01% 1608

Other funds holding CAI

Invesco's CAI Position: Q2 2026 in Review

Invesco reduced its Caris Life Sciences (CAI) stake by 89% in Q2 2026, selling an estimated $19.5M and leaving 132,103 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

Invesco first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $27.9M in Q4 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Invesco held 132,103 shares of Caris Life Sciences worth $2.35M as of Q2 2026.
  • Invesco sold 1,090,175 Caris Life Sciences shares in Q2 2026, an estimated $19.5M.
  • Caris Life Sciences made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2511 holding.
  • Invesco first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Invesco's Caris Life Sciences position peaked at $27.9M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.